Literature DB >> 16641044

Factors associated with hyperhomocysteinaemia in Mexican patients with rheumatoid arthritis.

M A Lopez-Olivo1, L Gonzalez-Lopez, A Garcia-Gonzalez, A I Villa-Manzano, A R Cota-Sanchez, M Salazar-Paramo, E Varon-Villalpando, E G Cardona-Muñoz, J I Gamez-Nava.   

Abstract

BACKGROUND: Hyperhomocysteinaemia is a factor related to the development of atherosclerosis in rheumatoid arthritis (RA). However, Hispanics with RA develop high rates of coronary disease; there are no studies about the frequency and factors related to high levels of homocysteine in Mexican patients.
OBJECTIVE: To evaluate the prevalence and characteristics associated with hyperhomocysteinaemia in Mexican patients with RA.
METHODS: One hundred and fifty-two patients with RA were compared with 153 controls. The assessment in RA included clinical characteristics, disease activity (RADAR), functioning (HAQ-Di and global functional status), comorbidity, and radiological damage. Laboratory determinations included total serum homocysteine (tHcy), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), and lipid profile.
RESULTS: Median levels of homocysteine were higher in RA compared with controls (11.3 vs. 9.3, p<0.001). Twenty per cent of the patients with RA had hyperhomocysteinaemia (>15 micromol/L) compared with 6% in controls (p<0.001). There was statistical association between hyperhomocysteinaemia in RA with male gender (p<0.001), impairment in the global functional status (p = 0.004), higher radiological damage (p = 0.001), and CRP (p = 0.04). There was no association with RADAR, HAQ-Di, or RF, methotrexate dose or duration of use. In the adjusted multivariate model, the two variables associated with higher risk for hyperhomocysteinaemia were male gender (OR = 4.2, 95% CI 2 to 12, p = 0.006) and higher radiological damage (III-IV) (OR = 3.4, 95% CI 1.3 to 9, p = 0.01).
CONCLUSIONS: Our data show a high prevalence of hyperhomocysteinaemia in Mexican patients with RA. More effort is required to evaluate and treat earlier this coronary risk factor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16641044     DOI: 10.1080/03009740510026922

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  12 in total

Review 1.  Novel risk factors for cardiovascular disease in rheumatoid arthritis.

Authors:  Jenny Amaya-Amaya; Juan Camilo Sarmiento-Monroy; Ruben-Dario Mantilla; Ricardo Pineda-Tamayo; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

2.  Serum homocysteine level in patients with ankylosing spondylitis.

Authors:  Bedriye Mermerci Başkan; Filiz Sivas; Lale Akbulut Aktekin; Yasemin Pekin Doğan; Kürşat Ozoran; Hatice Bodur
Journal:  Rheumatol Int       Date:  2009-03-15       Impact factor: 2.631

3.  MTHFR gene polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis based on 16 studies.

Authors:  Zahra Bagheri-Hosseinabadi; Danyal Imani; Hassan Yousefi; Mitra Abbasifard
Journal:  Clin Rheumatol       Date:  2020-03-14       Impact factor: 2.980

4.  Associations of methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms with genetic susceptibility to rheumatoid arthritis: a meta-analysis.

Authors:  Han Cen; Hua Huang; Li-Na Zhang; Li-Ya Liu; Li Zhou; Xia-Fei Xin; Ren-Jie Zhuo
Journal:  Clin Rheumatol       Date:  2016-07-16       Impact factor: 2.980

5.  Hyperhomocysteinemia in ankylosing spondylitis: prevalence and association with clinical variables.

Authors:  Laura Gonzalez-Lopez; Julia D Sanchez-Hernandez; Erika A G Aguilar-Chavez; Adolfo R Cota-Sanchez; Maria A Lopez-Olivo; Alberto I Villa-Manzano; Ricardo Ortega-Flores; Genadia L Espinoza-Magaña; Wendoline Rojo-Contreras; Ernesto G Cardona-Muñoz; Jorge I Gamez-Nava
Journal:  Rheumatol Int       Date:  2008-08-22       Impact factor: 2.631

6.  Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity.

Authors:  Jonathan L Marks; Christopher J Edwards
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-06       Impact factor: 5.346

7.  Cardiovascular disease in rheumatoid arthritis: a systematic literature review in latin america.

Authors:  Juan Camilo Sarmiento-Monroy; Jenny Amaya-Amaya; Juan Sebastián Espinosa-Serna; Catalina Herrera-Díaz; Juan-Manuel Anaya; Adriana Rojas-Villarraga
Journal:  Arthritis       Date:  2012-10-31

8.  Dyslipidaemia in rheumatological autoimmune diseases.

Authors:  Tracey E Toms; Vasileios F Panoulas; George D Kitas
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

9.  Therapeutic potential of folic acid supplementation for cardiovascular disease prevention through homocysteine lowering and blockade in rheumatoid arthritis patients.

Authors:  Mickael Essouma; Jean Jacques N Noubiap
Journal:  Biomark Res       Date:  2015-09-04

Review 10.  Cardiovascular involvement in autoimmune diseases.

Authors:  Jenny Amaya-Amaya; Laura Montoya-Sánchez; Adriana Rojas-Villarraga
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.